KNSA — Kiniksa Pharmaceuticals International Cashflow Statement
0.000.00%
Last trade - 00:00- $1.56bn
- $1.31bn
- $423.24m
- 66
- 22
- 55
- 45
Annual cashflow statement for Kiniksa Pharmaceuticals International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -161 | -158 | 183 | 14.1 | -43.2 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 22.4 | 28.6 | 28.1 | 29.3 | 34.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.32 | 0.689 | -22.6 | 1.35 | 24.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -137 | -126 | 5.81 | 13.3 | 25.7 |
| Capital Expenditures | -0.283 | -20.4 | -0.105 | -0.13 | -0.277 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -23.2 | 149 | -7.97 | -29.4 | 37.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -23.4 | 129 | -8.08 | -29.6 | 37.7 |
| Financing Cash Flow Items | -1.14 | — | -0.901 | -2.21 | -4.98 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 227 | 5.88 | 2.52 | 1.5 | 12.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 67.1 | 8.22 | 0.245 | -14.8 | 75.6 |